Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Obstructive Sleep Apnea-hypopnea
- Sponsor
- Poitiers University Hospital
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy.
- Last Updated
- 5 years ago
Overview
Brief Summary
The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer. Indeed, the level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor but the few studies published on the subject suggest an increased risk of development of OSAHS for these patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age\> 18 years old
- •Performance Status 0-2
- •Squamous cell carcinoma of the oropharynx treated with concomitant chemoradiotherapy
- •Treatment termination time greater than 6 months at inclusion
- •Tumor classification (American Joint Committee on Cancer 8th) T2-T4 N0-N3
- •Patient in complete remission at inclusion
- •patient's consent's obtained after information
Exclusion Criteria
- •Previous treatment for upper aerodigestive tract cancer
- •Incomplete radiotherapyTreatment
- •Neurological pathology wich may affect the functions of the upper aerodigestive tract
- •Pregnant or breastfeeding woman
- •Unweaned alcoholism
- •Tracheotomized patient at the time of the study
- •Patient under protection: subjects with guardianship or under law protection
- •No health insurance coverage
Outcomes
Primary Outcomes
Prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy.
Time Frame: Day 28
Number of patients with obstructive sleep apnea hypopnea syndrome after treatment combined chemoradiotherapy.
Secondary Outcomes
- Severity of OSAHS as a function of the post-therapeutic delay.(Day 28)